Home>>Peptides>>C-type natriuretic peptide (1-22) (human, rat, swine)

C-type natriuretic peptide (1-22) (human, rat, swine)

Catalog No.GC12034

C-type natriuretic peptide (1-22) (human, rat, swine), a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist.

Products are for research use only. Not for human use. We do not sell to patients.

C-type natriuretic peptide (1-22) (human, rat, swine) Chemical Structure

Cas No.: 127869-51-6

Size Price Stock Qty
500µg
$147.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Protocol

Cell experiment [1]:

Cell lines

CHO cells

Preparation Method

To evaluate the human NPR (hNPR) agonist activities of the test compounds(C-type natriuretic peptide (1-22) (human, rat, swine)), Using Chinese hamster ovarian (CHO) cells stably expressing hNPR-A or hNPR-B. Each compound was added to the cells in duplicate and incubated for 15 min. Cells were lysed.

Reaction Conditions

0.01-1000nM C-type natriuretic peptide (1-22) (human, rat, swine)for 15 min

Applications

C-type natriuretic peptide (1-22) (human, rat, swine) increased cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner.

Animal experiment [2]:

Animal models

Sprague Dawley (SD) rats

Preparation Method

Rats received C-type natriuretic peptide (1-22) (human, rat, swine) or ASB20123 by intravenous (iv) injection into the tail vein or subcutaneous (sc) injection into the back.

Dosage form

C-type natriuretic peptide (1-22) (human, rat, swine) iv (20 nmol/kg) or sc (50 nmol/kg)

Applications

C-type natriuretic peptide (1-22) (human, rat, swine) could be transported across the vascular wall and reach NPR-B in peripheral tissues.

References:

[1].Morozumi N, Yotsumoto T, Yamaki A, Yoshikiyo K, Yoshida S, Nakamura R, Jindo T, Furuya M, Maeda H, Minamitake Y, Kangawa K. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. doi: 10.1371/journal.pone.0212680. PMID: 30794654; PMCID: PMC6386482.

Background

C-type natriuretic peptide (1-22) (human, rat, swine) is an endogenous peptide found in plasma and cerebrospinal fluid[2]. C-type natriuretic peptide (CNP) is a member of the natriuretic peptide (NP) family [3]. It is also a potent, endothelial-derived relaxant and growth-inhibitory factor[6]. C-type natriuretic peptide (1-22) (human, rat, swine) is an agonist for the natriuretic peptide receptor NPR2 (NPRB) and has an affinity for NPR3 (NPRC). C-type natriuretic peptide (1-22) (human, rat, swine) can inhibit L-type calcium current in cardiomyocytes, has anti-proliferation effect in cardiac fibroblasts in vitro, and can promote vasodilation[7].

C-type natriuretic peptide (1-22) (human, rat, swine) increased cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner[1].

C-type natriuretic peptide (1-22) (human, rat, swine) could be transported across the vascular wall and reach NPR-B in peripheral tissues[1]. exogenous CNP(1-22) improved endochondral ossification and accelerated bone growth in mice after constant intravenous infusion at a large dose only[4]. I.c.v. administration of C-type natriuretic peptide (1-22) (human, rat, swine) in a dose of 2 nmol induced an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide[5].

References:
[1]. Morozumi N, Yotsumoto T, et,al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. doi: 10.1371/journal.pone.0212680. PMID: 30794654; PMCID: PMC6386482.
[2]. Minamino N, Makino Y, et,al.Characterization of immunoreactive human C-type natriuretic peptide in brain and heart. Biochem Biophys Res Commun. 1991 Aug 30;179(1):535-42. doi: 10.1016/0006-291x(91)91404-z. PMID: 1831979.
[3]. Potter LR, Yoder AR, et,al. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;(191):341-66. doi: 10.1007/978-3-540-68964-5_15. PMID: 19089336; PMCID: PMC4855512.
[4]. Yasoda A, Kitamura H, et,al. Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology. 2009 Jul;150(7):3138-44. doi: 10.1210/en.2008-1676. Epub 2009 Mar 12. PMID: 19282381; PMCID: PMC2703521.
[5]. Mazarati AM, HalÁszi E, et,al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24. doi: 10.1016/0024-3205(93)90227-t. PMID: 8423706.
[6]. Buckley MG, Jenkins GH, et,al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72. PMID: 11052928.
[7]. Pejchalova K, Krejci P, et,al.C-natriuretic peptide: an important regulator of cartilage. Mol Genet Metab. 2007 Nov;92(3):210-5. doi: 10.1016/j.ymgme.2007.06.014. Epub 2007 Aug 6. PMID: 17681481.

Chemical Properties

Cas No. 127869-51-6 SDF
Chemical Name (4R,5E,8Z,10S,11Z,14Z,16S,17Z,19S,20Z,22S,23E,26Z,28S,29Z,31S,32E,34S,35Z,37S,38E,40S,41Z,43S,44Z,47Z,49S,50Z,52R)-52-((Z)-((3Z,5S,6Z,8S,9Z,11S,12Z)-14-amino-5-(4-aminobutyl)-1,4,7,10,13-pentahydroxy-8-(hydroxymethyl)-11-isobutyl-3,6,9,12-tetraazatetradec
Canonical SMILES CC[C@]([C@@]1([H])/C(O)=N/C/C(O)=N\[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/C/C(O)=N/[C@@](/C(O)=N/C/C(O)=N\[C@@](C(O)=O)([H])CSSC[C@@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/CN)([H])CC(C)C)([H])CO)([H])CCCCN)([H])/C(O)=N/[C@@](/C(O)=N/C
Formula C93H157N27O28S3 M.Wt 2197.61
Solubility Soluble in Water Storage Desiccate at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 0.455 mL 2.2752 mL 4.5504 mL
5 mM 0.091 mL 0.455 mL 0.9101 mL
10 mM 0.0455 mL 0.2275 mL 0.455 mL
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Reviews

Review for C-type natriuretic peptide (1-22) (human, rat, swine)

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for C-type natriuretic peptide (1-22) (human, rat, swine)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.